An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

2019119 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Haematology

Volume 6, Issue 4, pp. e194-e203

Field-Weighted Citation Impact: 12.58